Status:
UNKNOWN
Autologous Killer Cell Therapy in Colon Cancer Patients
Lead Sponsor:
Sabz Biomedicals
Collaborating Sponsors:
Ministry of Health and Medical Education
Digestive Diseases Research Institute, Tehran University of Medical Sciences, Iran
Conditions:
Colon Cancer Stage IV
Eligibility:
All Genders
40+ years
Phase:
PHASE1
PHASE2
Brief Summary
This study aims to evaluate the safety and efficacy of activated and expanded autologous cytokine-killer cells in controlling disease recurrence in colon cancer patients with liver metastasis. 20 pati...
Eligibility Criteria
Inclusion
- Patients with histologically confirmed colorectal cancer at stage IV
- ECOG performance status 0-2
- Adequate cardiac/renal/hepatic function
- Adequate bone marrow function (blood cell count)
Exclusion
- Patients that have received prior chemotherapy or immune cell therapy
- Patients that have previously participated in another clinical trial
- History of positive test result for HIV, HBV, HCV, HTLV-1, syphilis
- Presence of Active infections
- Patients with immunodeficiencies, autoimmunities, or severe allergies
- Receiving immunosuppressive regimens
Key Trial Info
Start Date :
February 9 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03329664
Start Date
February 9 2020
End Date
January 1 2022
Last Update
March 15 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gene Therapy Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences
Tehran, Iran